<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227770</url>
  </required_header>
  <id_info>
    <org_study_id>XH-16-017</org_study_id>
    <nct_id>NCT03227770</nct_id>
  </id_info>
  <brief_title>The Benefit of Hemodialysis Plus Hemoperfusion on Mortality</brief_title>
  <official_title>A Randomized, Open-label, Multi-centre Trial Comparing Hemodialysis Plus Hemoperfusion Versus Hemodialysis Alone in Adult Patients With End-stage Renal Disease (HD/HPvsHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yangpu District Central Hospital Affiliated to Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, open-label, randomized controlled trial aims to investigate the efficacy
      of hemoperfusion (HP) combined with hemodialysis (HD) by evaluating all-cause mortality and
      cardiovascular mortality in maintenance hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this HD/HPvsHD trial, we plan to enroll 1364 maintenance hemodialysis patients. Eleven
      medical centers in Shanghai Metropolitan area have explicitly expressed interest to
      participate. Participants will be randomized to receive hemodialysis plus hemoperfusion or
      hemodialysis alone at a 1:1 ratio after 1-month run-in period. In both arms, patients will
      receive low-flux hemodialysis at a frequency of 2 times a week and hemodiafiltration at a
      frequency of once a week. In the experiment group, in addition to the treatments in the
      control arm, hemoperfusion will be conducted once every two weeks using a HA130 resin
      hemoperfusion apparatus containing 130ml resin. Follow-up is scheduled at 3, 6, 12, 18, and
      24 months after randomization, and will consist the following: routine physical examinations,
      standard lab panels (blood routine, liver/kidney functions, tests of the coagulation system,
      etc.), chest X-ray, electrocardiogram, echocardiography, heart function rating (based on New
      York Heart Association grading). Dialysis adequacy defined by standard Kt/V will be
      calculated. Adverse events will be assessed according to the international conference on
      harmonization guidelines. The primary outcomes will include 24-month all-cause mortality.
      Secondary outcomes will include cardiovascular-related mortality, the occurrence of major
      cardiovascular events and the quality of life (Kidney Disease Quality of Life Short Form).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>From date of enrollment until the end of study, assessed up to 96 weeks</time_frame>
    <description>Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular-related mortality and major cardiovascular events (MACEs)</measure>
    <time_frame>From date of enrollment until the end of study, assessed up to 96 weeks</time_frame>
    <description>Major cardiovascular events events including angina pectoris, acute myocardial infarction, severe arrhythmia, congestive heart failure, myocarditis, pericarditis, cardiac surgery or peripheral vascular surgery, stroke and peripheral vascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>From date of enrollment until the end of study, assessed up to 96 weeks</time_frame>
    <description>Assessment of quality of life using the KDQOL-SF (Kidney Disease Quality of Life Short Form) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1364</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>regular hemodialysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-flux hemodialysis treatment at a frequency of 2 times a week and online-hemodiafiltration treatment at a frequency of once a week, with each treatment session lasting 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hemoperfusion combined with hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of hemodialysis and hemoperfusion treatment once every two week</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemoperfusion combined with hemodialysis</intervention_name>
    <description>Hemoperfusion combined with hemodialysis treatment will perform once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)</description>
    <arm_group_label>hemoperfusion combined with hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemodialysis</intervention_name>
    <description>Low-flux hemodialysis treatment at a frequency of 2 times a week and online-hemodiafiltration treatment at a frequency of once a week, with each treatment session lasting 4 hours.</description>
    <arm_group_label>regular hemodialysis</arm_group_label>
    <arm_group_label>hemoperfusion combined with hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet all of the following criteria are eligible:

          1. Age at 18-75 years old

          2. Regular blood purification treatment at least 3 months before enrolled in this study

          3. Standard Kt/V ≥ 1.2

        Subjects with one of more of the following conditions will be excluded:

          1. White blood cell count &lt; 4×10^9/L and / or platelet count &lt; 100×10^9/L

          2. Cerebral hemorrhage in the past 12 weeks

          3. MACEs in the past 8 weeks

          4. Severe heart failure (New York Heart Association [NYHA] class III or IV)

          5. Active gastrointestinal bleeding, or coagulation dysfunction

          6. Malignant tumor

          7. Active infection

          8. Pregnancy or lactation

          9. Participating in clinical trials in the past 3 months 10) Mental disabilities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gengru Jiang, doctoral</last_name>
    <role>Study Director</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei LU, doctoral</last_name>
    <phone>+86-13651608106</phone>
    <email>luweixh@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyong Guo, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueyi Deng, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>RenJi Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Ni, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaonong Chen, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai 6th People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niansong Wang, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijie Yuan, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Ding, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital, Tongji University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Yu, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoqiang Ding, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yangpu District Central Hospital Affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Zhou, doctoral</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei LU, doctoral</last_name>
      <phone>+86-13651608106</phone>
      <email>luweixh@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Gengru Jiang</investigator_full_name>
    <investigator_title>Director of Renal Division, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Hemoperfusion</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The mortality data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

